Having trouble accessing articles? Reset your cache.

H1N1 VLP influenza vaccine: Final Phase II data

Novavax previously reported preliminary data from the first stage of the trial showing that single doses of 15 and 45 µg of the

Read the full 238 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE